Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-04-21 / J Transl Med 2020 04;18(1):176TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma /von 2020-02-01 / J Immunother Cancer 2020 02;8(1)Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
/in Dendritic Cells, Malignant Melanoma /von 2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-11-15 / Hum Vaccin Immunother 2020 04;16(4):742-755Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-11 / Biomedicines 2019 Oct;7(4)Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-09 / Front Immunol 2019;10:2353Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects
/in Hyperthermia, International Publications, Malignant Melanoma /von 2019-08-17 / Int J Mol Sci 2019 Aug;20(16)A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells